SCNI
Scinai Immunotherapeutics Ltd.
Price Chart
Latest Quote
$0.32
-0.02 (-4.60%)
Current Price
| Previous Close | $0.34 |
| Open | $0.33 |
| Day High | $0.34 |
| Day Low | $0.31 |
| Volume | 260,885 |
Stock Information
| Shares Outstanding | 5.17M |
| Total Debt | $3.50M |
| Cash Equivalents | $2.96M |
| Revenue | $1.21M |
| Net Income | $-3.17M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.66M |
| P/E Ratio | 0.18 |
| EPS (TTM) | $1.75 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.30M |
| Sales | $1.21M |
| Income | $-3.17M |
| Book/sh | $0.71 |
| Cash/sh | $0.57 |
| Employees | 45 |
Financial Ratios
| Quick Ratio | 1.16 |
| Current Ratio | 1.35 |
| Debt/Eq | 29.73 |
Returns & Margins
| ROA | -35.85% |
| ROE | -29.19% |
| Operating Margin | -504.50% |
| Profit Margin | -261.37% |
Ownership
| Insider Ownership | 8.00% |
| Institutional Ownership | 2.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 1.37 |
| P/B | 0.45 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.41 |
| SMA50 | $0.51 |
| SMA200 | $0.90 |
| RSI | 29.08 |
| ATR | 0.0509 |
| Shares Float | 3.16M |
| Short Float | 2.48% |
| Short Ratio | 0.41 |
| Volatility | 2.05 |
| Rel Volume | 0.53 |
Performance History
| Week | -0.92% |
| Month | -36.61% |
| Quarter | -54.33% |
| 6 Months | -61.67% |
| YTD | -55.89% |
| Year | -85.81% |
| 3 Years | -97.60% |
| 5 Years | -99.90% |
| 10 Years | -99.92% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.32 | 273,400 |
| 2026-06-17 | $0.34 | 972,600 |
| 2026-06-16 | $0.35 | 755,500 |
| 2026-06-15 | $0.36 | 2,641,000 |
| 2026-06-12 | $0.33 | 1,213,300 |
| 2026-06-11 | $0.32 | 157,300 |
| 2026-06-10 | $0.33 | 345,300 |
| 2026-06-09 | $0.35 | 353,700 |
| 2026-06-08 | $0.41 | 185,600 |
| 2026-06-05 | $0.41 | 1,266,200 |
| 2026-06-04 | $0.44 | 186,400 |
| 2026-06-03 | $0.45 | 186,300 |
| 2026-06-02 | $0.48 | 127,300 |
| 2026-06-01 | $0.50 | 357,400 |
| 2026-05-29 | $0.45 | 472,800 |
| 2026-05-28 | $0.45 | 126,900 |
| 2026-05-27 | $0.45 | 234,400 |
| 2026-05-26 | $0.48 | 117,700 |
| 2026-05-22 | $0.46 | 150,700 |
| 2026-05-21 | $0.50 | 108,300 |
| 2026-05-20 | $0.48 | 888,200 |
| 2026-05-19 | $0.51 | 170,500 |
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies. It has collaboration partnerships with Max Planck Society and University Medical Center Gottingen for the development of NanoAb candidates; and Recipharm Israel Ltd for the development of biologics and small-molecule programs. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is based in Jerusalem, Israel.
đ° Latest News
No news articles available at the moment. Check back later for updates on SCNI.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,963,000 | $1,238,000 | $0 | $0 |
| Cost Of Revenue | $3,963,000 | $1,238,000 | $0 | $0 |
| Total Revenue | $1,311,000 | $658,000 | $0 | $0 |
| Operating Revenue | $1,311,000 | $658,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $359,000 | $1,422,000 | $3,801,000 | $0 |
| Total Expenses | $8,853,000 | $9,296,000 | $9,706,000 | $11,061,000 |
| Other Income Expense | $-416,000 | $14,766,000 | $3,091,000 | $2,235,000 |
| Net Non Operating Interest Income Expense | $-349,000 | $-1,332,000 | $115,000 | $3,030,000 |
| Total Other Finance Cost | $10,000 | $10,000 | $8,000 | $21,000 |
| Interest Expense Non Operating | $359,000 | $1,422,000 | $3,801,000 | $0 |
| Operating Expense | $4,890,000 | $8,058,000 | $9,706,000 | $11,061,000 |
| Other Operating Expenses | - | - | $-9,000 | - |
| Rent Expense Supplemental | - | - | - | - |
| General And Administrative Expense | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,307,000 | $4,796,000 | $-6,500,000 | $-5,796,000 |
| Net Interest Income | $-349,000 | $-1,332,000 | $115,000 | $3,030,000 |
| Interest Income | $20,000 | $100,000 | $3,924,000 | $3,051,000 |
| Normalized Income | $-7,891,000 | $-6,573,820 | $-9,591,000 | $-8,031,000 |
| Net Income From Continuing And Discontinued Operation | $-8,307,000 | $4,796,000 | $-6,500,000 | $-5,796,000 |
| Total Operating Income As Reported | $-7,542,000 | $-8,638,000 | $-9,706,000 | $-11,061,000 |
| Net Income Common Stockholders | $0 | $0 | $-6,500,000 | $-5,796,000 |
| Net Income | $-8,307,000 | $4,796,000 | $-6,500,000 | $-5,796,000 |
| Net Income Including Noncontrolling Interests | $-8,307,000 | $4,796,000 | $-6,500,000 | $-5,796,000 |
| Net Income Continuous Operations | $-8,307,000 | $4,796,000 | $-6,500,000 | $-5,796,000 |
| Pretax Income | $-8,307,000 | $4,796,000 | $-6,500,000 | $-5,796,000 |
| Special Income Charges | $0 | $14,759,000 | $0 | $0 |
| Interest Income Non Operating | $20,000 | $100,000 | $3,924,000 | $3,051,000 |
| Operating Income | $-7,542,000 | $-8,638,000 | $-9,706,000 | $-11,061,000 |
| Gross Profit | $-2,652,000 | $-580,000 | $0 | $0 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $0.00 | $0.00 | $-16.00 | $-40.00 |
| Basic EPS | $0.00 | $0.00 | $-16.00 | $-40.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $3,396,180 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,111,000 | $-6,899,000 | $-5,276,000 | $-7,469,000 |
| Total Unusual Items | $-416,000 | $14,766,000 | $3,091,000 | $2,235,000 |
| Total Unusual Items Excluding Goodwill | $-416,000 | $14,766,000 | $3,091,000 | $2,235,000 |
| Reconciled Depreciation | $1,421,000 | $1,649,000 | $514,000 | $562,000 |
| EBITDA (Bullshit earnings) | $-6,527,000 | $7,867,000 | $-2,185,000 | $-5,234,000 |
| EBIT | $-7,948,000 | $6,218,000 | $-2,699,000 | $-5,796,000 |
| Diluted Average Shares | $2,334,865 | $806,368 | $390,657 | $188,519 |
| Basic Average Shares | $2,334,865 | $806,368 | $390,657 | $188,519 |
| Diluted NI Availto Com Stockholders | $0 | $0 | $-6,500,000 | $-5,796,000 |
| Preferred Stock Dividends | $-8,307,000 | $4,796,000 | - | - |
| Gain On Sale Of Security | $-416,000 | $7,000 | $3,091,000 | $2,235,000 |
| Research And Development | $2,369,000 | $5,532,000 | $5,210,000 | $5,765,000 |
| Selling General And Administration | $2,521,000 | $2,526,000 | $4,505,000 | $5,296,000 |
| Other Special Charges | - | $-14,759,000 | - | - |
| Other Gand A | - | - | - | - |
| Rent And Landing Fees | - | - | - | - |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $8,103,000 | $9,977,000 | $-4,569,000 | $-1,760,000 |
| Total Assets | $11,626,000 | $13,448,000 | $17,472,000 | $27,067,000 |
| Total Non Current Assets | $9,572,000 | $11,057,000 | $12,025,000 | $12,697,000 |
| Current Assets | $2,054,000 | $2,391,000 | $5,447,000 | $14,370,000 |
| Restricted Cash | $150,000 | $131,000 | $140,000 | $140,000 |
| Prepaid Assets | $75,000 | $79,000 | $71,000 | $45,000 |
| Receivables | $168,000 | $217,000 | $366,000 | $110,000 |
| Other Receivables | $95,000 | $134,000 | $366,000 | $110,000 |
| Accounts Receivable | $73,000 | $83,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $1,661,000 | $1,964,000 | $4,870,000 | $14,075,000 |
| Cash And Cash Equivalents | $1,661,000 | $1,964,000 | $4,870,000 | $14,075,000 |
| Other Non Current Assets | - | - | - | - |
| Cash Financial | - | - | - | - |
| Debt | ||||
| Total Debt | $2,267,000 | $2,086,000 | $20,561,000 | $21,542,000 |
| Long Term Debt And Capital Lease Obligation | $1,938,000 | $1,662,000 | $20,165,000 | $21,160,000 |
| Long Term Debt | $294,000 | $260,000 | $19,368,000 | $20,082,000 |
| Current Debt And Capital Lease Obligation | $329,000 | $424,000 | $396,000 | $382,000 |
| Net Debt | - | - | $14,498,000 | $6,007,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,523,000 | $3,471,000 | $22,041,000 | $28,827,000 |
| Total Non Current Liabilities Net Minority Interest | $1,938,000 | $1,665,000 | $20,261,000 | $26,489,000 |
| Derivative Product Liabilities | $0 | $3,000 | $96,000 | $5,329,000 |
| Current Liabilities | $1,585,000 | $1,806,000 | $1,780,000 | $2,338,000 |
| Current Deferred Liabilities | $90,000 | $225,000 | $0 | - |
| Payables And Accrued Expenses | $1,166,000 | $1,157,000 | $1,384,000 | $1,956,000 |
| Payables | $407,000 | $376,000 | $535,000 | $716,000 |
| Accounts Payable | $407,000 | $376,000 | $535,000 | $716,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $2,476,000 | $4,350,000 | $-4,569,000 | $-1,760,000 |
| Preferred Stock Equity | $5,627,000 | $5,627,000 | - | - |
| Total Equity Gross Minority Interest | $8,103,000 | $9,977,000 | $-4,569,000 | $-1,760,000 |
| Stockholders Equity | $8,103,000 | $9,977,000 | $-4,569,000 | $-1,760,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,740,000 | $-1,740,000 | $-1,740,000 | $-2,007,000 |
| Other Equity Adjustments | $-1,740,000 | $-1,740,000 | $-1,740,000 | $-2,007,000 |
| Retained Earnings | $-125,846,000 | $-117,539,000 | $-122,335,000 | $-115,835,000 |
| Other | ||||
| Ordinary Shares Number | $13,872,899,584 | $3,411,983,584 | $1,857,169,984 | $989,290,784 |
| Share Issued | $13,872,899,584 | $3,411,983,584 | $1,857,169,984 | $989,290,784 |
| Tangible Book Value | $2,476,000 | $4,350,000 | $-4,569,000 | $-1,760,000 |
| Invested Capital | $2,770,000 | $4,610,000 | $14,799,000 | $18,322,000 |
| Working Capital | $469,000 | $585,000 | $3,667,000 | $12,032,000 |
| Capital Lease Obligations | $1,973,000 | $1,826,000 | $1,193,000 | $1,460,000 |
| Total Capitalization | $8,397,000 | $10,237,000 | $14,799,000 | $18,322,000 |
| Additional Paid In Capital | $130,062,000 | $123,629,000 | $119,506,000 | $116,082,000 |
| Capital Stock | $5,627,000 | $5,627,000 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $5,627,000 | $5,627,000 | $0 | - |
| Long Term Capital Lease Obligation | $1,644,000 | $1,402,000 | $797,000 | $1,078,000 |
| Current Deferred Revenue | $90,000 | $225,000 | $0 | - |
| Current Capital Lease Obligation | $329,000 | $424,000 | $396,000 | $382,000 |
| Current Accrued Expenses | $759,000 | $781,000 | $849,000 | $1,240,000 |
| Net PPE | $9,572,000 | $11,057,000 | $12,025,000 | $12,697,000 |
| Accumulated Depreciation | $-5,876,000 | $-4,456,000 | $-2,808,000 | $-2,421,000 |
| Gross PPE | $15,448,000 | $15,513,000 | $14,833,000 | $15,118,000 |
| Leases | $3,723,000 | $3,723,000 | $3,723,000 | $3,915,000 |
| Other Properties | $3,948,000 | $4,018,000 | $3,342,000 | $3,040,000 |
| Machinery Furniture Equipment | $7,777,000 | $7,772,000 | $321,000 | $332,000 |
| Properties | $0 | $0 | $0 | $0 |
| Construction In Progress | - | $0 | $7,447,000 | $7,831,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $484,000 |
| Employee Benefits | - | - | - | - |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | - | - |
| Buildings And Improvements | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-6,055,000 | $-6,347,000 | $-10,019,000 | $-8,101,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-6,031,000 | $-6,335,000 | $-9,382,000 | $-7,265,000 |
| Cash Flow From Continuing Operating Activities | $-6,031,000 | $-6,335,000 | $-9,382,000 | $-7,265,000 |
| Operating Gains Losses | $-3,000 | $-93,000 | $-4,140,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-24,000 | $-12,000 | $-637,000 | $-836,000 |
| Investing Cash Flow | $-24,000 | $-12,000 | $-637,000 | $-836,000 |
| Cash Flow From Continuing Investing Activities | $-24,000 | $-12,000 | $-637,000 | $-836,000 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $5,770,000 | $2,000,000 | $139,000 | $932,000 |
| Financing Cash Flow | $5,770,000 | $3,441,000 | $1,086,000 | $6,776,000 |
| Cash Flow From Continuing Financing Activities | $5,770,000 | $3,441,000 | $1,086,000 | $6,776,000 |
| Net Common Stock Issuance | $5,770,000 | $2,000,000 | $139,000 | $932,000 |
| Common Stock Issuance | $5,770,000 | $2,000,000 | $139,000 | $932,000 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $143,000 | $833,000 | $916,000 |
| End Cash Position | $1,811,000 | $2,095,000 | $5,010,000 | $14,215,000 |
| Beginning Cash Position | $2,095,000 | $5,010,000 | $14,215,000 | $17,517,000 |
| Effect Of Exchange Rate Changes | $1,000 | $-9,000 | $-272,000 | $-1,977,000 |
| Changes In Cash | $-285,000 | $-2,906,000 | $-8,933,000 | $-1,325,000 |
| Net PPE Purchase And Sale | $-24,000 | $-12,000 | $-637,000 | $-836,000 |
| Purchase Of PPE | $-24,000 | $-12,000 | $-637,000 | $-836,000 |
| Change In Working Capital | $163,000 | $112,000 | $-796,000 | $271,000 |
| Change In Other Current Liabilities | $147,000 | $-314,000 | $-58,000 | $-156,000 |
| Change In Other Current Assets | $89,000 | $284,000 | $43,000 | $153,000 |
| Change In Payables And Accrued Expense | $-126,000 | $1,000 | $-491,000 | $134,000 |
| Change In Payable | $-126,000 | $1,000 | $-491,000 | $134,000 |
| Change In Account Payable | $31,000 | $-156,000 | $-150,000 | $-175,000 |
| Change In Receivables | $53,000 | $141,000 | $-290,000 | $140,000 |
| Changes In Account Receivables | $10,000 | $-83,000 | $0 | - |
| Other Non Cash Items | $392,000 | $-13,481,000 | $401,000 | $-3,904,000 |
| Stock Based Compensation | $303,000 | $682,000 | $1,139,000 | $1,602,000 |
| Depreciation Amortization Depletion | $1,421,000 | $1,649,000 | $514,000 | $562,000 |
| Depreciation And Amortization | $1,421,000 | $1,649,000 | $514,000 | $562,000 |
| Depreciation | $1,421,000 | $1,649,000 | $514,000 | $562,000 |
| Gain Loss On Investment Securities | $-3,000 | $-93,000 | $-4,140,000 | - |
| Net Income From Continuing Operations | $-8,307,000 | $4,796,000 | $-6,500,000 | $-5,796,000 |
| Proceeds From Stock Option Exercised | - | $1,441,000 | $947,000 | $5,844,000 |
| Repayment Of Debt | - | - | - | - |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Sale Of PPE | - | - | - | - |
| Interest Received Cfo | - | - | - | - |
| Interest Paid Cfo | - | - | - | - |
| Pension And Employee Benefit Expense | - | - | - | - |
Fetched: 2026-06-19